Mobilization of hematopoietic stem cells with cyclophosphamide or cytarabine in combination with granulocyte colony-stimulating factor in patients with multiple myeloma, who are candidates for autologous stem cell transplantation
https://doi.org/10.18821/0234-5730-2017-62-4-180-187
Abstract
In our research the comparison of different regimes of mobilization of HSC were carried out. First regime: conduct stimulation of granulopoiesis using granulocyte colony-stimulating factor (GCSF). Other regimes: of mobilization with chemotherapy (cyclophosphamide or cytarabine). The efficiency and the toxicity were assessed. The grafts with satisfactory cellularity were obtained in 91% patients. The number of CD34+ cell/ml were obtained in the first apheresis and from whole mobilization in patients with complete remission (CR) were more than the number of in patients with < CR. CD34+ cell number in the blood correlate well with total number of CD34+ yielded from apheresis in same day. The number of CD34+ cells/microliter yielded from mobilization was more in group with сhemomobilization than in group with GCSF only. In comparison two groups of сhemomobilization: the number of CD34+ in peripheral blood in day apheresis was more in group with AraC-GCSF; р = 0.173. There was revealed lesser toxicity in group with AraC-GCSF.
About the Authors
D. V. Babenetskaya
Federal Almazov North-West Medical Research Centre
Russian Federation
Russian Federation
Babenetskaya D.V., hematologist
St. Petersburg, 197341
D. V. Motorin
Federal Almazov North-West Medical Research Centre
Russian Federation
Russian Federation
St. Petersburg, 197341
A. V. Petrov
Federal Almazov North-West Medical Research Centre
Russian Federation
Russian Federation
St. Petersburg, 197341
Yu. A. Alekseeva
Federal Almazov North-West Medical Research Centre
Russian Federation
Russian Federation
St. Petersburg, 197341
A. Yu. Zaritskey
Federal Almazov North-West Medical Research Centre
Russian Federation
Russian Federation
St. Petersburg, 197341
References
1. Kumar S.K., Rajkumar S.V., Dispenzieri A., Lacy M.G., Hayman S.R., Buadi F.K., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008; 111(5): 2516–20.
2. Ljungman P., Bregni M., Brune M., Cornelissen J., de Witte T., Dini G., et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant. 2010; 45(2): 219–34.
3. Salvino M.A., Ruiz J. Hematopoietic progenitor cell mobilization for autologous transplantation – a literature review. Rev. Bras. Hematol. Hemoter. 2016; 38(1): 28–36.
4. Olivieri A., Marchetti M., Lemoli R., Tarella C., Iacone A., Lanza F., et al. Proposed definition of ‘poor mobilizer’ in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplant. 2012; 47(3): 342–51.
5. Mohty M., Hubel K., Kroger N., Aljurf M., Apperley J., Basak G.W., et al. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2014; 49(7): 865–872.
6. Giralt S., Costa L., Schriber J., Dipersio J., Maziarz R., McCarty J., et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol. Blood Marrow Transplant. 2014; 20(3): 295–308.
7. Ford C.D., Greenwood J., Anderson J., Snow G., Petersen F.B. CD34+cell adhesion molecule profiles differ between patients mobilized with granulocyte-colony-stimulating factor alone and chemotherapy followed by granulocyte-colony-stimulating factor. Transfusion. 2006; 46(2): 193–8.
8. Pokrovskaya O.S. Mechanism of action and clinical activity of CXCR4 Plerixafor in stem cell mobilization. Clinical oncohematology. Basic research and clinical practice. Russian journal (Klinicheskaya onkogematologiya. Fundamental’nye issledovaniya i klinicheskaya praktika). 2012; 5(4): 371–9. (in Russian)
9. Mikhailova N.B., Alianskiy A.L., Kondakova E.V., Zalyalov Yu.P., Babenko E.V., Sergeev V.S., et al. Mobilization of hematopoietic stem cells (HSCs) by using Plerixafor (Mozobail) in combination with colonystimulating factor in patients with previous failure transplant procurement for autotransplantation of HSCs. Russian Journal of Modern Oncology (Sovremennaya onkologiya). 2014; 16(1): 48–52. (in Russian)
10. Bilgin Y.M., de Greef G.E. Plerixafor for stem cell mobilization: the current status. Curr. Opin. Hematol. 2016; 23(1): 67–71.
11. DiPersio J.F., Micallef I.N., Stiff P. J., Bolwell B.J., Maziarz R.T., Jacobsen E., et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin lymphoma. J. Clin. Oncol. 2009; 27(28): 4767–73.
12. Basak G.W., Jaksic O., Koristek Z., Mikala G., Basic-Kinda S., Mayer J., et al. Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells. Eur. J. Haematol. 2011; 86(6): 488–95.
13. Hubel K., Fresen M.M., Apperley J.F., Basak G.W., Douqlas K. W., Gabriael I.H., et al. European data on stem cell mobilization with plerixafor in non-Hodgkin’s lymphoma, Hodgkin’s lymphoma and multiple myeloma patients—a subgroup analysis of the European Consortium of stem cell mobilization. Bone Marrow Transplant. 2012; 47(8): 1046–50.
14. Malard F., Kroger N., Gabriel I.H., Hubel K., Apperley J.F., Basak G.W., et al. Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. Biol. Blood Marrow Transplant. 2012; 18(2): 314–7.
15. Basak G.W., Wiktor-Jedrzejczak W., Apperley J.F., Douglas K.W., Gabriel I.H., Geraldes C., et al. Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF. Bone Marrow Transplant. 2012; 47(7): 1003–5.
16. Kucher M.A., Motalkina M.S., Klimova O.U., Kondakova E.V., Kalashnikova O. B., Alekeev S.M., et al. Plerixafor in patients with decreased mobilizing ability of autologous hematopoietic stem cells. Clinical oncohematology. Basic research and clinical practice. Russian journal (Klinicheskaya onkogematologiya. Fundamental’nye issledovaniya i klinicheskaya praktika). 2016; 9(2): 155–61. (in Russian)
17. Gertz M.A. Current status of stem cell mobilization. Br. J. Haematol. 2010; 150: 647–62.
18. Sheppard D., Bredeson C., Allan D., Tay J. Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies. Biol. Blood Marrow Transplant. 2012; 18(8): 1191–203.
19. Pokrovskaya O.S., Mendeleeva L.P., Urnova E.S., Gaponova T.V., Galceva I. V., Kuzmina L.A., et al. The effect of bortezomib on the effectiveness of the mobilization of hematopoietic stem cells in the blood of patients with multiple myeloma. Terapeutic archive. Russian journal.
20. (Terapevticheskiy arkhiv). 2012; 84(7): 35–41. (in Russian)
21. Giebel S., Sadus-Wojciechowska M., Najda J., Czerw T., ClowalaKosinska M., Holowiecki J., et al. Very high efficacy of intermediate-dose cytarabine in combination with G-CSF as a second-line mobilization of hematopoietic stem cells. Int. J. Hematol. 2012; 96(2): 287–9.
22. Calderon-Cabrera C., Carmona Gonzalez M., Martin J., Rios Herranz E., Noquerol P., De la Cruz F., et al. Intermediate doses of cytarabine plus granulocyte–colony-stimulating factor as an effective and safe regimen for hematopoietic stem cell collection in lymphoma patients with prior mobilization failure. Transfusion. 2015; 55(4): 875–9.
23. Giebel S., Kruzel T., Czerw T., Sadus-Wojciechowska M., Najda J., Chmielowska E., et al. Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizers. Bone Marrow Transplant. 2013; 48(7): 915–21.
24. Giebel S., Sadus-Wojciechowska M., Halaburda K., Drozd-Sokolowska J., Wierzbowska A., Najda J., et al. Increased efficacy of intermediatedose cytarabine + G-CSF compared to DHAP + G-CSF for stem cell mobilization in patients with lymphoma: an analysis by the polish lymphoma research group. Ann. Hematol. 2016; 95(2): 263–9.
25. Wallis W., Qazilbash M. Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy? World J. Transplant. 2017; 7(5): 250–9.
26. Durie B.G., Salmon S.E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975; 36(3): 842–54.
27. Giralt S., Costa L., Schriber J., Dipersio J., Maziarz R., McCarty J., et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol. Blood Marrow Transplant. 2014; 20(3): 295–308.
28. Stepanov A.A., Korotaev E.B., Bessmeltsev S.S., Rabinovich V. I., Astahova L.P., Ponomarev S.A., et al. Algorithm obtaining of the hematopoietic stem cells peripheral blood for autologous transplantation. Russian biomedical journal. Russian journal. (Russkij biomedicinskij zhurnal). 2013; 14(2): 255–65. (in Russian)
29. Sung A., Grima D. Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF versus G-CSF alone. Bone Marrow Transplant. 2013; 48(11): 1444–9.
30. Duong H.K., Savani B.N., Copelan E., Devine S., Costa L.J., Winqard J.R., et al. Peripheral Blood Progenitor Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. Biol. Blood Marrow Transplant. 2014; 20(9): 1262–73.
31. Hamadani M., Kochuparambil S.T., Osman S., Cumpston A., Leadmon S., Bunner P., et al. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. Biol. Blood Marrow Transplant. 2012; 18(7): 1128–35.
32. Sizemore C.A., Laporte J., Holland H.K., Mccollum J., Westerman J., Morris L.E., et al. A comparison of toxicity and mobilization efficacy following two different doses of cyclophosphamide for mobilization of hematopoietic stem cells in non-Hodgkin’s lymphoma patients. Biol. Blood Marrow Transplant. 2010; 16(2): 206.
33. Tuchman S., Bacon W. Cyclophosphamide-Based Hematopoietic Stem Cell Mobilization Before Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma. J. Clin. Apher. 2015; 30(3): 176–82.
34. Dingli D., Nowakowski G.S., Dispenzieri A., Lacy M.Q., Hayman S., Litzow M.R., et al. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clin. Lymphoma Myeloma. 2006; 6(5): 384–8.
Review
For citations:
Babenetskaya D.V., Motorin D.V., Petrov A.V., Alekseeva Yu.A., Zaritskey A.Yu. Mobilization of hematopoietic stem cells with cyclophosphamide or cytarabine in combination with granulocyte colony-stimulating factor in patients with multiple myeloma, who are candidates for autologous stem cell transplantation. Russian journal of hematology and transfusiology. 2017;62(4):180-187. (In Russ.) https://doi.org/10.18821/0234-5730-2017-62-4-180-187
Views:
5
Email this article 
